389 related articles for article (PubMed ID: 22421192)
1. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.
Mross K; Frost A; Steinbild S; Hedbom S; Büchert M; Fasol U; Unger C; Krätzschmar J; Heinig R; Boix O; Christensen O
Clin Cancer Res; 2012 May; 18(9):2658-67. PubMed ID: 22421192
[TBL] [Abstract][Full Text] [Related]
2. Regorafenib.
Ettrich TJ; Seufferlein T
Recent Results Cancer Res; 2014; 201():185-96. PubMed ID: 24756792
[TBL] [Abstract][Full Text] [Related]
3. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies.
Geoerger B; Morland B; Jiménez I; Frappaz D; Pearson ADJ; Vassal G; Maeda P; Kincaide J; Mueller U; Schlief S; Teufel M; Ploeger BA; Cleton A; Agostinho AC; Marshall LV
Eur J Cancer; 2021 Aug; 153():142-152. PubMed ID: 34157616
[TBL] [Abstract][Full Text] [Related]
5. A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors.
Weekes C; Lockhart AC; Lee JJ; Sturm I; Cleton A; Huang F; Lenz HJ
Int J Cancer; 2019 Nov; 145(9):2450-2458. PubMed ID: 30958892
[TBL] [Abstract][Full Text] [Related]
6. Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics.
Sunakawa Y; Furuse J; Okusaka T; Ikeda M; Nagashima F; Ueno H; Mitsunaga S; Hashizume K; Ito Y; Sasaki Y
Invest New Drugs; 2014 Feb; 32(1):104-12. PubMed ID: 23553067
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor.
Aprile G; Macerelli M; Giuliani F
BioDrugs; 2013 Jun; 27(3):213-24. PubMed ID: 23435872
[TBL] [Abstract][Full Text] [Related]
9. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial.
Eisen T; Joensuu H; Nathan PD; Harper PG; Wojtukiewicz MZ; Nicholson S; Bahl A; Tomczak P; Pyrhonen S; Fife K; Bono P; Boxall J; Wagner A; Jeffers M; Lin T; Quinn DI
Lancet Oncol; 2012 Oct; 13(10):1055-62. PubMed ID: 22959186
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomes.
Fukudo M; Asai K; Tani C; Miyamoto M; Ando K; Ueno N
Invest New Drugs; 2021 Oct; 39(5):1422-1431. PubMed ID: 33830408
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
Duffaud F; Mir O; Boudou-Rouquette P; Piperno-Neumann S; Penel N; Bompas E; Delcambre C; Kalbacher E; Italiano A; Collard O; Chevreau C; Saada E; Isambert N; Delaye J; Schiffler C; Bouvier C; Vidal V; Chabaud S; Blay JY;
Lancet Oncol; 2019 Jan; 20(1):120-133. PubMed ID: 30477937
[TBL] [Abstract][Full Text] [Related]
12. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib for cancer.
Strumberg D; Schultheis B
Expert Opin Investig Drugs; 2012 Jun; 21(6):879-89. PubMed ID: 22577890
[TBL] [Abstract][Full Text] [Related]
15. The development of regorafenib and its current and potential future role in cancer therapy.
Davis SL; Eckhardt SG; Messersmith WA; Jimeno A
Drugs Today (Barc); 2013 Feb; 49(2):105-15. PubMed ID: 23462625
[TBL] [Abstract][Full Text] [Related]
16. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.
Belum VR; Wu S; Lacouture ME
Invest New Drugs; 2013 Aug; 31(4):1078-86. PubMed ID: 23700287
[TBL] [Abstract][Full Text] [Related]
17. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
Moore M; Hirte HW; Siu L; Oza A; Hotte SJ; Petrenciuc O; Cihon F; Lathia C; Schwartz B
Ann Oncol; 2005 Oct; 16(10):1688-94. PubMed ID: 16006586
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.
Wilhelm SM; Dumas J; Adnane L; Lynch M; Carter CA; Schütz G; Thierauch KH; Zopf D
Int J Cancer; 2011 Jul; 129(1):245-55. PubMed ID: 21170960
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors.
Yamada K; Yamamoto N; Yamada Y; Nokihara H; Fujiwara Y; Hirata T; Koizumi F; Nishio K; Koyama N; Tamura T
Clin Cancer Res; 2011 Apr; 17(8):2528-37. PubMed ID: 21372218
[TBL] [Abstract][Full Text] [Related]
20. A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.
Cao J; Zhang J; Peng W; Chen Z; Fan S; Su W; Li K; Li J
Cancer Chemother Pharmacol; 2016 Aug; 78(2):259-69. PubMed ID: 27299749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
